KOD Stock Analysis: Kodiak Sciences | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 2.056m USD | 12M Return: 468.8% | US50015M1099 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 26.4M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 8 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Kodiak Sciences Inc. (NASDAQ: KOD) is a clinical-stage biopharmaceutical company based in Palo Alto, California, focused on developing therapeutics for retinal diseases. Its lead candidate, tarcocimab tedromer (KSI-301), is an anti-VEGF antibody biopolymer being evaluated across multiple Phase 3 and Phase 2/3 studies targeting high-prevalence retinal conditions including wet age-related macular degeneration (AMD), diabetic retinopathy, retinal vein occlusion, and diabetic macular edema. The companys earlier-stage pipeline includes KSI-501, a bispecific antibody biopolymer conjugate targeting IL-6 and VEGF, and KSI-101, a bispecific protein developed for patients with retinal fluid and inflammation. Originally incorporated in 2009 as Oligasis, LLC, the company rebranded to Kodiak Sciences in September 2015 and went public in October 2018.
As a clinical-stage biotechnology company, Kodiak does not yet have approved products generating commercial revenue, and its value is largely tied to the progression of its clinical pipeline rather than current sales. The retinal disease market it targets is substantial and growing, driven by aging populations and the rising prevalence of conditions such as AMD and diabetic eye disease, making it a key focus area within the ophthalmology biopharmaceutical sector.
- Phase 3 tarcocimab failure clouds regulatory approval prospects
- Competition from Eylea HD and Vabysmo pressures market share
- Cash runway tightens as pipeline burn rate accelerates
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.63 > 0.02 and ΔFCF/TA -17.03 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.62 > 3% & CFO -158.5m > Net Income -242.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.49 > 1.5 & < 3 |
| Outstanding Shares: last quarter (62.6m) vs 12m ago 18.66% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 10.38%; Δ -10.38% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.31 (Total Current Assets 131.4m - Total Current Liabilities 52.8m) / Total Assets 256.8m |
| B: -6.55 (Retained Earnings -1.68b / Total Assets 256.8m) |
| C: -0.96 (EBIT TTM -246.4m / Avg Total Assets 256.8m) |
| D: 0.31 (Book Value of Equity 61.1m / Total Liabilities 195.7m) |
| Altman-Z'' = -25.47 = D |
As of September 29, 2026, the stock is trading at USD 89.92 with a total of 38,398,805 shares traded. Over the past week, the price has changed by +177.36%, over one month by +138.39%, over three months by +138.26% and over the past year by +468.75%.
Current recommended Stop Loss: 87.30 (which is 2.9% or 1.2 ATR below the current price).
Kodiak Sciences has received a consensus analysts rating of 2.83. Therefore, it is recommended to hold KOD.
- StrongBuy: 1
- Buy: 0
- Hold: 2
- Sell: 3
- StrongSell: 0
| Analysts Target Price | 69.6 | -22.6% |
P/B = 33.6591
Revenue TTM = 0.0 USD
EBIT TTM = -246.4m USD
EBITDA TTM = -220.8m USD
Long Term Debt = 85.9m USD (estimated: total debt 95.7m - short term 9.81m)
Short Term Debt = 9.81m USD (from shortTermDebt, last quarter)
Debt = 148.5m USD (from shortLongTermDebtTotal, last quarter) + Leases 52.8m
Net Debt = 22.6m USD (calculated: Debt 148.5m - CCE 125.9m)
Enterprise Value = 2.08b USD (2.06b + Debt 148.5m - CCE 125.9m)
Interest Coverage Ratio = unknown (Ebit TTM -246.4m / Interest Expense TTM 0.0)
EV/FCF = -12.77x (Enterprise Value 2.08b / FCF TTM -162.7m)
FCF Yield = -7.83% (FCF TTM -162.7m / Enterprise Value 2.08b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 8.09 (Enterprise Value 2.08b / Total Assets 256.8m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 148.5m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -194.7m (EBIT -246.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.01 (Total Current Assets 131.4m / Total Current Liabilities 65.4m)
Debt / Equity = 2.43 (Debt 148.5m / totalStockholderEquity, last quarter 61.1m)
Debt / EBITDA = -0.10 (negative EBITDA) (Net Debt 22.6m / EBITDA -220.8m)
Debt / FCF = -0.14 (negative FCF - burning cash) (Net Debt 22.6m / FCF TTM -162.7m)
Total Stockholder Equity = 88.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -94.25% (Net Income -242.0m / Total Assets 256.8m)
RoE = -273.2% (Net Income TTM -242.0m / Total Stockholder Equity 88.6m)
RoCE = -141.2% (out of range, set to none) (EBIT -246.4m / Capital Employed (Equity 88.6m + L.T.Debt 85.9m))
RoIC = -91.03% (negative operating profit) (NOPAT -194.7m / Invested Capital 213.9m)
WACC = 11.56% (E(2.06b)/V(2.20b) * Re(12.39%) + D(148.5m)/V(2.20b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 12.39% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 73.02 | Cagr: 8.15%
[DCF] Fair Price = unknown (Cash Flow -162.7m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.81 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-1.01 | Chg30d=-1.27% | Revisions=-62% | Analysts=5
EPS current Year (2026-12-31): EPS=-3.99 | Chg30d=-0.92% | Revisions=-62% | GrowthEPS=+7.7% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-3.75 | Chg30d=-5.62% | Revisions=-57% | GrowthEPS=+6.1% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -82% (up=0, down=14)